About Lactobacillus paracasei
Renamed from Lactobacillus paracasei to Lacticaseibacillus paracasei (2020). CNCM I-1518 has a systematic review/meta-analysis for common infectious diseases; Lpc-37 has an RCT (ChillEx) for exam-related stress markers. Evidence is strain-specific.
What Lactobacillus paracasei supports
- Moderate evidence for immune support (specific strains)
- Lpc-37 studied for stress-related markers in a single RCT
How much Lactobacillus paracasei to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1–20
billion_cfu
Lpc-37 studied around 5-17.5 billion CFU/day; no universal dose. Often presence-only in blends; nominal range.
Clinical evidence
Moderate clinical evidence. Moderate: strain-specific RCTs and one infection meta-analysis.
NIH Fact Sheet